ABIOMED

Traded on the St. Petersburg Stock Exchange
Abiomed is company that develops and manufactures external and implantable circulatory support devices.
P/E adj.
Net profit (adj.)
P/B
Book value
P/FCF
FCF
Yield
Growth potential

ABIOMED balance sheet

Report period2017 2018 2019 2020 2021 Q3 22
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

ABIOMED cash flows

Report period2017 2018 2019 2020 2021 Q3 22 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

ABIOMED multipliers

Report period2017 2018 2019 2020 2021 Q3 22 TTM
P/E
P/E adj.
E/P
E adj./P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

ABIOMED profitability

Report period2017 2018 2019 2020 2021 Q3 22 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
ABIOMED assets
ABIOMED cash flows
ABIOMED news
23.12.2022
Johnson & Johnson closed the deal to buy Abiomed for $16.6 billion, or $380 per share. Abiomed shareholders may also receive another $35.00 per share, subject to certain commercial and clinical milestones.
Source: {source} pictogram johnsonandjohnson.gcs-web.com
Pictogram next
01.11.2022
Johnson & Johnson is buying Abiomed for $16.6 billion, or $380 per share. Abiomed shareholders will also be entitled to another $35.00 per share if certain commercial and clinical milestones are met. Transaction is expected to close in the first quarter of 2023.
Source: {source} pictogram johnsonandjohnson.gcs-web.com
Pictogram next
28.04.2022
ABIOMED's GAAP net income for fiscal year 2022 was $136.505 million, down 39.5% from $225.525 million in the previous year. Revenue increased 21.8% to $1.032 billion from $0.847 billion a year earlier.
Source: {source} pictogram investors.abiomed.com
Pictogram next
03.02.2022
Net income of ABIOMED under GAAP for 9 months of fiscal year 2022 was $76.18 million, down 2.2 times from $168.669 million in the previous year. Revenue increased 25.7% to $761.903 million from $606.277 million a year earlier.
Source: {source} pictogram investors.abiomed.com
Pictogram next
All ABIOMED news
General information
Company nameABIOMED
Tags#medtech, #s&p500 index
SectorHealth Care / Health Care Equipment & Services / Health Care Equipment & Supplies / Health Care Equipment
Business address22 CHERRY HILL DR DANVERS MA 01923 9787775410
Mailing address22 CHERRY HILL DRIVE DANVERS MA 01923
Websitewww.abiomed.com